Last Updated : October 22, 2024
Details
Project Status:
Active
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0094-000
Expected finish date:
Familial hypercholesterolemia is a genetic disorder caused by homozygous or heterozygous mutations of the low-density lipoprotein receptor gene, apolipoprotein B gene, or PCSK9 gene. It is characterized by very elevated levels of low-density lipoprotein cholesterol and an increased risk of early onset atherosclerotic cardiovascular disease.
This query will focus on conducting a drug utilization study that will include the monoclonal antibody inhibitors of PCSK9, namely evolocumab and alirocumab, to determine their utilization in Canada and the characteristics of patients.
Last Updated : October 22, 2024